Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 10:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 452 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ALS - Amyotrophic Lateral Sclerosis Clear all
Suspended No phase listed Observational Accepts healthy volunteers

SOD1 Kinetics Measurements in ALS Patients

NCT03449212
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Familial, Amyotrophic Lateral Sclerosis, Sporadic
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 4, 2026, 10:01 PM EDT
Completed Not applicable Interventional

Trial of Resistance and Endurance Exercise in Amyotrophic Lateral Sclerosis (ALS)

NCT01521728
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Resistance Exercise, Endurance Exercise, Stretching/Range-of-Motion
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Charlestown, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Oct 4, 2026, 10:01 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

NCT05137665
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Target ALS Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2031
U.S. locations
10
States / cities
Phoenix, Arizona • San Diego, California • Georgetown, District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 4, 2026, 10:01 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD

NCT04220021
View directory record Official record
Conditions
C9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia
Interventions
Metformin
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 4, 2026, 10:01 PM EDT
Recruiting Phase 1 Interventional

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

NCT06665165
View directory record Official record
Conditions
ALS
Interventions
AMX0114, Placebo
Drug · Other
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
La Jolla, California • Washington D.C., District of Columbia • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 4, 2026, 10:01 PM EDT
Recruiting No phase listed Observational

Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

NCT03225144
View directory record Official record
Conditions
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 110 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 4, 2026, 10:01 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)

NCT02000713
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MRI, Clinical Exam
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 4, 2026, 10:01 PM EDT
Completed No phase listed Observational

Genomic Translation for Amyotrophic Lateral Sclerosis Care

NCT02795897
View directory record Official record
Conditions
ALS
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Aurora, Colorado • Ann Arbor, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 4, 2026, 10:01 PM EDT
Not listed No phase listed Observational

Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy

NCT03330353
View directory record Official record
Conditions
PSP - Progressive Supranuclear Palsy, PD - Parkinson's Disease, AD - Alzheimer's Disease, ALS (Amyotrophic Lateral Sclerosis)
Interventions
Pupillometry
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 4, 2026, 10:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis

NCT04721717
View directory record Official record
Conditions
Spinal Cord Injuries, Multiple Sclerosis, Transverse Myelitis, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 4, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Safety of Engensis in Participants With Amyotrophic Lateral Sclerosis

NCT04632225
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Engensis, Placebo
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • Chicago, Illinois • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 4, 2026, 10:01 PM EDT
Completed Phase 2 Interventional

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT01089010
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, 250 mg CK-2017357, 500 mg CK-2017357
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
15
States / cities
Phoenix, Arizona • Fresno, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 4, 2026, 10:01 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

NCT05395624
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Interventions
18F-OP-801
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
San Francisco, California • Stanford, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 4, 2026, 10:01 PM EDT
Completed Phase 1 Interventional

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
BHV-0223
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Oct 4, 2026, 10:01 PM EDT
Completed Phase 2 Interventional Results available

Therapy in Amyotrophic Lateral Sclerosis (TAME)

NCT02118727
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia
Interventions
Memantine, Placebo (for Memantine)
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Irvine, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 4, 2026, 10:01 PM EDT
Recruiting No phase listed Observational

A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

NCT07259980
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Tofersen
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 4, 2026, 10:01 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ALS Research Collaborative

NCT06885918
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS (Amyotrophic Lateral Sclerosis), ALS With Frontotemporal Dementia (ALS/FTD), Motor Neuron Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
ALS Therapy Development Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2035
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 4, 2026, 10:01 PM EDT
Recruiting No phase listed Observational

NYSCF Scientific Discovery Biobank

NCT06203106
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, Alzheimer Disease, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Batten Disease, Corticobasal Degeneration, Dementia, Frontotemporal Dementia, Huntington Disease, Lewy Body Disease, Multiple Sclerosis, Multiple System Atrophy, Parkinson Disease, Parkinson's Disease and Parkinsonism, Progressive Supranuclear Palsy, INAD, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Macular Degeneration, Ovarian Cancer, Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, PTSD, Post Traumatic Stress Disorder
Interventions
Biological Sample Collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
30 Days and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2045
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 4, 2026, 10:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

NCT05945784
View directory record Official record
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute, Traumatic Brain Injury, SCI - Spinal Cord Injury, Ehlers-Danlos Syndromes (EDS), Lupus Erythematosus, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Graves Disease, Muscular Dystrophies
Interventions
Use of Rare Beauty makeup products
Other
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 4, 2026, 10:01 PM EDT
Recruiting Not applicable Interventional

MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System

NCT05936619
View directory record Official record
Conditions
Paralysis; Quadriplegic, Quadraplegia, Tetraplegia, Tetraplegic Motor Dysfunction Following Brainstem or Spinal Cord Injury, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis (ALS), Brainstem Stroke, Paralysis, Brain-computer Interface
Interventions
Mind Extender (MindEx)
Device
Lead sponsor
Nader Pouratian
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 10:01 PM EDT
Terminated Phase 2 Interventional

A Study of STRO4 in Patients Amyotrophic Lateral Sclerosis (ALS)

NCT06910384
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
STR04
Biological
Lead sponsor
New England Cell Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 4, 2026, 10:01 PM EDT
Terminated Phase 2 Interventional Results available

Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients

NCT04066244
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BLZ945
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 4, 2026, 10:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx

NCT03986671
View directory record Official record
Conditions
Obstructive Sleep Apnea, Amyotrophic Lateral Sclerosis, Muscular Dystrophies, Healthy
Interventions
Transmembrane EMG Oropharynx Probe
Device
Lead sponsor
Powell Mansfield Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 4, 2026, 10:01 PM EDT
Completed No phase listed Observational

F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis

NCT02414230
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Drug: F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 4, 2026, 10:01 PM EDT